The new Sentinel Network--improving the evidence of medical-product safety.

In a congressionally mandated effort to improve postmarketing safety surveillance, the FDA is seeking to develop the Sentinel Network to link vast amounts of data on patients, medication use, and adverse events. Dr. Richard Platt and colleagues argue that the best solution is a distributed data network.